High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.
Abbott Laboratories (NYSE:ABT) reached a US$385 million settlement tied to the 2022 infant formula recall and Sturgis plant shutdown. The agreement resolves civil claims from families, states, and other plaintiffs alleging product safety failures and gaps in compliance with federal standards. The settlement follows U.S. Department of Justice and multi state investigations into Abbott's infant formula operations, with no admission of liability. This civil resolution of Abbott's 2022 formula...
Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes.
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.
While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Despite Abbott Laboratories' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.
On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.7% and th
Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.
The S&P 500 Index ($SPX ) (SPY ) today is down -0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.28%. September E-mini S&P futures (ESU26 ) are down -0.40%, and September E-mini Nasdaq futures...
Abbott Laboratories stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and traditional market multiples currently point to the shares trading at a discount. The share price is down about 30.7% over the past year, which has pushed investor sentiment lower while opening a potential valuation gap. Progress in colorectal cancer diagnostics and partnerships in continuous glucose monitoring can support long term cash...
Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.
Passive income is characterized by its ability to generate revenue without requiring the earner’s continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence. The more passive income can help cover rising costs, such as mortgages, insurance, taxes, and other expenses, the easier it ... 5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential
The U.S. Department of Justice has closed its criminal investigation into Abbott Laboratories' Michigan baby formula plant. Authorities are pursuing civil penalties tied to alleged manufacturing failures that contributed to a national baby formula shortage. The outcome clarifies a key regulatory risk and shifts the focus to civil, rather than criminal, enforcement. Abbott Laboratories, ticker NYSE:ABT, now faces a clearer regulatory path as the criminal probe gives way to civil penalties...
Abbott Laboratories has reached a proposed settlement that will see civil penalties paid under the US False Claims Act.
The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.
(Updates with DOJ's response in the fifth and sixth paragraphs.) Abbott Laboratories (ABT) will n
Abbott Laboratories (ABT) will not face criminal charges after the US Department of Justice closed a
Some prosecutors believed they had enough to charge Abbott Laboratories, but senior officials opted for civil settlement.
Abbott Laboratories (NYSE:ABT) is among the Best Brain-Computer Interface Stocks. On June 4, Reuters reported a federal judge ruled that Abbott Laboratories (NYSE:ABT) must face a proposed class-action lawsuit alleging it misled consumers by marketing PediaSure Grow & Gain drinks as “clinically proven” to help children grow. US District Judge Paul Engelmayer said labeling featuring a […]
While STERIS has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
If you are wondering whether Abbott Laboratories at around US$91.07 is a bargain or a value trap, you will want to look closely at what the current valuation is really telling you. The stock has risen 3.7% over the past week and 8.0% over the past month, yet it remains down 26.7% year to date and down 30.3% over the last year, which raises fair questions about how sentiment and risk perception have shifted. Recent headlines have focused on Abbott Laboratories as a large healthcare player,...
The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.
Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.
Abbott Laboratories has trailed the Dow Jones Industrial Average over the past year, but analysts remain highly optimistic about the company's long-term growth prospects.
Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
